NASDAQ:VOR Vor Biopharma 11/7/2024 Earnings Results & Report $19.42 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$19.11 -0.31 (-1.60%) As of 05:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Vor Biopharma met analyst earnings expectations in results released November 7, 2024. The company reported EPS of -$8.00 versus the -$8.00 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details Report DateNovember 7, 2024TimeAfter Market Closes Vor Biopharma EPS ResultsActual EPS-$8.00Consensus EPS -$8.00Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersVor Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Vor Biopharma Earnings FAQ Did Vor Biopharma beat earnings estimates for the quarter? Vor Biopharma (NASDAQ:VOR) reported earnings of -$8.00 per share for the quarter, matching the consensus estimate of -$8.00. The report was announced on Thursday, November 7, 2024. Vor Biopharma Earnings HeadlinesIs Narrower Quarterly Loss Altering The Investment Case For Vor Biopharma Stock?November 12, 2026 | finance.yahoo.comVor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL FranchiseNovember 12, 2026 | globenewswire.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. | Weiss Ratings (Ad)Vor Biopharma (VOR) Stock Looks Reasonable After a 94% Five Year SlideNovember 6, 2026 | finance.yahoo.comHC Wainwright Forecasts Stronger Earnings for Vor BiopharmaNovember 6, 2026 | americanbankingnews.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 4, 2026 | globenewswire.comSee More Vor Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vor Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vor Biopharma and other key companies, straight to your email. Email Address About Vor BiopharmaVor Biopharma (NASDAQ:VOR) is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33. These programs have been developed primarily for acute myeloid leukemia (AML); neither is an approved treatment. Founded in 2015 and based in Cambridge, Massachusetts, Vor has focused its clinical development and research on cancer therapies. Its work has been centered on the U.S. biotechnology and clinical-research landscape.View Vor Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.